Literature DB >> 26455350

Multicomponent Reactions, Union of MCRs and Beyond.

Tryfon Zarganes-Tzitzikas1, Ajay L Chandgude1, Alexander Dömling2.   

Abstract

Multicomponent reactions (MCRs), which are located between one- and two-component and polymerization reactions, provide a number of valuable conceptual and synthetic advantages over stepwise sequential approaches towards complex and valuable molecules. To address current limitations in the number of MCRs and the resulting scaffolds, the concept of union of MCRs was introduced two decades ago by Dömling and Ugi and is rapidly advancing, as is apparent by several recently published works. MCR technology is now widely recognized for its impact on drug discovery projects and is strongly endorsed by industry in addition to academia. Clearly, novel scaffolds accessible in few steps including MCRs will further enhance the field of applications. Additionally, broad expansion of MCR applications in fields such as imaging, materials science, medical devices, agriculture, or futuristic applications in stem cell therapy and theragnostics or solar energy and superconductivity are predicted.
Copyright © 2015 The Chemical Society of Japan and Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords:  drug discovery; isocyanides; medicinal chemistry; molecular diversity; multicomponent reactions

Mesh:

Substances:

Year:  2015        PMID: 26455350     DOI: 10.1002/tcr.201500201

Source DB:  PubMed          Journal:  Chem Rec        ISSN: 1528-0691            Impact factor:   6.771


  32 in total

1.  Isocyanide-Based Multicomponent Reactions of Free Phenylboronic Acids.

Authors:  Constantinos G Neochoritis; Tryfon Zarganes-Tzitzikas; Michaela Novotná; Tatiana Mitríková; Zefeng Wang; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  Eur J Chem       Date:  2019-08-15

2.  With unprotected amino acids to tetrazolo peptidomimetics.

Authors:  Rudrakshula Madhavachary; Qian Wang; Alexander Dömling
Journal:  Chem Commun (Camb)       Date:  2017-07-27       Impact factor: 6.222

3.  β-Carbolinone Analogues from the Ugi Silver Mine.

Authors:  Rudrakshula Madhavachary; Naganaboina Naveen; Yuanze Wang; Qian Wang; Markella Konstantinidou; Alexander Dömling
Journal:  European J Org Chem       Date:  2018-04-17

4.  An Efficient Passerini Tetrazole Reaction (PT-3CR).

Authors:  Ajay L Chandgude; Alexander Dömling
Journal:  Green Chem       Date:  2016-05-19       Impact factor: 10.182

5.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

6.  Synthesis and antitumoral activity of novel analogues monastrol-fatty acids against glioma cells.

Authors:  Franciele S De Oliveira; Patrick M De Oliveira; Luana M Farias; Rafael C Brinkerhoff; Rui Carlos M A Sobrinho; Tamara M Treptow; Caroline R Montes D'Oca; Marcelo A G Marinho; Mariana A Hort; Ana P Horn; Dennis Russowsky; Marcelo G Montes D'Oca
Journal:  Medchemcomm       Date:  2018-05-30       Impact factor: 3.597

7.  Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure.

Authors:  Eman M M Abdelraheem; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  J Org Chem       Date:  2016-09-15       Impact factor: 4.354

8.  Synthesis of fused polycyclic β-carboline derivatives using Ugi-4CR followed by cascade cyclization.

Authors:  Vipin Kumar; Anjali Saxena; Ranjan Patra; Devalina Ray; Hong-Yu Li; Biswajit Saha
Journal:  Mol Divers       Date:  2022-06-02       Impact factor: 2.943

Review 9.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

10.  Tetramethylguanidine-functionalized melamine as a multifunctional organocatalyst for the expeditious synthesis of 1,2,4-triazoloquinazolinones.

Authors:  Mahnoush Keshavarz; Mohammad G Dekamin; Manouchehr Mamaghani; Mohammad Nikpassand
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.